Invex Therapeutics (ASX: IXC) executive director and chief science officer Alex Sinclair joins Small Caps to discuss the company’s Evolve phase III trial which is now underway and evaluating its lead drug Presendin in patients with idiopathic intracranial hypertension (IHH).

IIH is a rapidly growing disease, with incidences rising 350% over the last 10 year.

Around 240 newly diagnosed IIH patients will be recruited to the trial which will be open at 40 sites around the world.

Articles:
https://smallcaps.com.au/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals/
https://smallcaps.com.au/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial/

For more information on Invex Therapeutics:
https://smallcaps.com.au/stocks/IXC/

See omnystudio.com/listener for privacy information.